Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01524887 · ClinicalTrials.gov registry record · Phase 3
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
NCT01524887 is a Phase 3 study that was terminated before completion, run by Baxalta now part of Shire. The registered enrollment target is 508 participants.
The verdict
NCT01524887, a Phase 3 study, was terminated before completion, sponsored by Baxalta now part of Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
Study Summary
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
Interventions
- BIOLOGICAL Immune Globulin Intravenous (Human), 10% Solution
- BIOLOGICAL Human albumin 0.25%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2012-01-23 |
| Est. Completion | 2013-07-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01524887
The ClinicalTrials.gov registry entry for NCT01524887 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Immune Globulin Intravenous (Human), 10% Solution is the first listed.
NCT01524887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01524887 about?
NCT01524887 is a clinical study titled "Phase 3 IGIV, 10% in Alzheimer´s Disease". The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
What is the current status of trial NCT01524887?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2012-01-23. Estimated completion is 2013-07-16.
What interventions are being tested in trial NCT01524887?
The interventions under investigation include: Immune Globulin Intravenous (Human), 10% Solution (BIOLOGICAL), Human albumin 0.25% (BIOLOGICAL).
Who is sponsoring clinical trial NCT01524887?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.